Could a cancer drug tame tough seizures? tiny trial begins
NCT ID NCT07095933
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 29 times
Summary
This pilot study tests whether everolimus, a drug usually used for cancer, can help control seizures in people with drug-resistant focal epilepsy. Only 5 adults aged 18-60 will take the drug during seizure events for 12 weeks. The goal is to see if seizure frequency drops and if the drug is safe enough for a larger trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Beijing
RECRUITINGBeijing, Beijing Municipality, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
everolimus
What this could lead to
If it works, this could point toward a new medication option for people with hard-to-control epilepsy, taken only during seizure events.
What could go wrong
This is a very early pilot study with only 5 people, so results may not apply broadly. The drug may not reduce seizures or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.